Generated by AI
Summary of Oct 23's posts. Generated by AI.
Summary of Apr 1's posts. Generated by AI.
Summary of Apr 2's posts. Generated by AI.
Investors talking about ORIC also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.
Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies that address resistance to treatment. The company’s research pipeline centers on precision oncology, hormone-dependent cancers, and key tumor dependencies, with current programs designed to target mechanisms that limit the effectiveness of existing cancer medicines. Its product candidates include therapies in clinical development for genetically defined cancers and prostate cancer, along with additional discovery-stage oncology programs. Oric Pharmaceuticals operates as a single business segment and concentrates its efforts on advancing research, clinical development, and translational science for cancer treatment. The company is headquartered in South San Francisco, California, with additional operations supporting its development work in the United States. Its role in the market is to contribute experimental oncology candidates to the broader pipeline of targeted cancer therapeutics.
Website240 E. Grand Ave
South San Francisco, CA, 94080
United States